Just been following the Novo Nordisk situation, and there's actually something interesting happening beneath the surface here. Yeah, the stock got hammered lately—down nearly 15% after disappointing Q4 numbers and rough 2026 guidance. But if you dig a bit deeper, there's some genuine positive signals that most people seem to be overlooking.

Here's the thing: Novo Nordisk's oral Wegovy just launched, and early traction is actually solid. Now, you'd think that's obvious good news, right? But here's where it gets interesting—Eli Lilly basically just confirmed it's even better than it sounds. Their executive VP Kenneth Custer came out saying that oral Wegovy is mostly attracting new patients, not just cannibalizing the injectable version. His exact words were that it's "expanding the market." That's huge validation from your biggest competitor.

Why does that matter? Because the whole weight loss drug space has been plagued by injection hassles. People hate needles, storage is complicated (needs refrigeration but not freezing), and travel becomes a nightmare. An oral option changes the game entirely. And Eli Lilly's basically admitting it—they're watching this and realizing their own oral GLP-1 candidate can't come soon enough.

But here's the catch: even with oral Wegovy performing well, Novo Nordisk still expects sales to decline in 2026. The oral version helps, sure, but it's not enough to offset competitive pressure and drug pricing headwinds. So the real recovery story isn't about Wegovy at all.

What could actually move the needle? CagriSema waiting for approval, amycretin in phase 3 trials, plus a whole pipeline of other weight loss candidates in phase 2 and 3. If any of these hit, that's when the stock could see real momentum. The company's basically betting on next-gen medicines, not just defending current market share.

With the stock at fresh 52-week lows right now, there's definitely risk here. But long-term, if they can execute on that pipeline, this could be a solid contrarian play. The market's clearly punishing them for near-term headwinds, but the foundation for a recovery is actually there.